Global Thought Leaders Outline Unmet Needs, Opportunities in Anxiety and Depression Market in New MedPredict Report
Posted on: Monday, 21 July 2008, 15:01 CDT
SCOTTSDALE, Ariz., July 21 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for anxiety and depression therapies.
In this report, entitled "MedPredict Thought Leader Insight & Analysis: Anxiety & Depression Q3 2008," a panel of physician experts from North America and Europe discuss the strengths and weaknesses of a variety of branded and near-market antidepressants and anxiolytics.
"In our last report we highlighted three key unmet needs -- higher core efficacy, more durable remissions and lower side effects," said Dr. Jeffery Berk, MedPredict's president and one of the authors of the report. "This new report identifies the characteristics that next-generation therapeutics will need to go beyond those benefits and deliver enhanced cognition, reduced anhedonia, and relief from pain and fatigue." Some of the questions addressed by MedPredict's panel:
-- How will FDA's approval of Lilly's Cymbalta for neuropathic diabetic pain and fibromyalgia impact its use in depression? How important is a pain indication in treatment of depression?
-- In this challenging regulatory and economic environment, what will new therapeutics need to demonstrate to displace current usage of SSRIs, SRNIs and generic antidepressants? How should these studies be designed?
-- How do thought leaders view the strengths and weaknesses of Lilly's Cymbalta vs. Wyeth's Pristiq?
-- What are the differences in prescribing trends among psychiatrists compared with primary care physicians?
-- Which of the new molecules and mechanisms in development are most promising? The panel covers triple reuptake inhibitors, antipsychotics, MAOIs, Beta-3 agonists, nicotinic acetylcholine receptor agonists, NMDA/glutamatergics, GABA, CRH and more.
Companies/Partnerships discussed include: Abbott, AstraZeneca, Bristol-Myers Squibb, Forest/Lundbeck, Forest/Cypress/Pierre Fabre, Lilly, Lilly/Boehringer Ingelheim, Lundbeck/Takeda, Merck-Serono, Ono, Novartis/Servier, Pfizer, Sanofi-Aventis, Sepracor, Targacept/AstraZeneca, Wyeth, and others.
This report can be purchased by contacting MedPredict. About MedPredict
MedPredict (http://www.medpredict.com/) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.
MedPredict
CONTACT: Elizabeth Mathews of MedPredict, +1-513-271-1924,liz@medpredict.com
Web site: http://www.medpredict.com/
Source: PRNewswire
Related Articles
- New Options for Treatment of RA and Lupus are Focus of Rheumatology Thought Leader Panel
- Thought Leader Panel Assesses Anticoagulants Market in the Wake of European Society of Cardiology Conference in New MedPredict Report
- Clickability Hosts Webinar with Marketing 2.0 and Social Media Leaders on Building Brands, Driving Leads and Increasing Revenue
- MRI Reveals Depression and Pain Link
- Solar Industry Needs Stable Markets to Grow: Business Leader
- Painkillers Should All Stay on Market, Despite Heart Risks: FDA Panel
- Celebrex Should Stay on Market, Despite Heart Risks: FDA Panel
- Leading Projector Manufacturers Fujitsu, Hitachi, Panasonic, Sanyo and Sony Join Forces With Epson to Educate the Market About Benefits of Three-Panel, Liquid Crystal Display Technology
- HP First to Reach Milestone of 100,000 Blade Servers Sold; Worldwide Blade Market and System Performance Leader Delivers Expanded Management and Linux Capabilities to New Customers
- Business: Nokia left out in mobile phone boom: Lack of mid market handsets hits Finnish leader
 |
 |
User Comments (0)
RSS Feeds